Document is current

Article History

Received: 27 November 2023

Accepted: 5 January 2024

First Online: 16 January 2024

Declarations

:

: The present study was reviewed by the ethics committee of the University of Regensburg. No professional ethical or legal concerns exist (Ethics Committee Number: 22-3012-101). Before study participation, all participants will be informed about the project in writing and must confirm their willingness to participate in writing. Room for potential questions about the planned study will be given at any time. Serious side effects are not to be expected, as the study will take place within the framework of routine medical care, and admission to the day hospice is basically possible regardless of study participation. With the exception of the written or oral surveys, no other study-specific measures will take place on the participants according to the study protocol. The information and education sheets were formulated concisely and clearly so as not to risk overburdening critically ill patients.

: Not applicable.

: UK, UV-K, AH, AH, MF, MR, AB, and MK declare that they have no competing interests. FK indicates consulting activities for Elsevier, Astellas, GSK, MSD, Novartis, Pierre Fabre, Sanofi, and Servier.

: Prior to the allocation of funding the study protocol has undergone a review by the scientific staff of the Bavarian State Ministry of Health and Care (sponsor). All questions were clarified.